ConductScience.org, home

Comparison · NCT01139658-69cceebc

Total Knee Replacement vs Total Hip Replacement: Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Total Knee Replacement vs Total Hip Replacement: Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge. Trial comparisons, record NCT01139658-69cceebc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01139658-69cceebc

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03220.02170.0474wilson
Risk in group 20.04740.03550.063wilson
Risk difference, group 1 minus group 2-0.0152-0.0340.00415newcombe hybrid score
Risk ratio, group 1 over group 20.6790.4171.11log
Odds ratio, group 1 over group 20.6690.4031.11log
Number needed to treat, for one fewer participant with the outcome on Total Knee Replacement than on Total Hip Replacement65.8from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Total Knee ReplacementPatients undergoing elective total knee replacement (TKR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting.24746OG000
Group 2Total Hip ReplacementPatients undergoing elective total hip replacement (THR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting.44929OG001

Outcome

Type
SECONDARY
Title
Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge
Description
Time frame
11 weeks
Population
Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.

Source ClinicalTrials.gov

Trial

Title
Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA
NCT number
NCT01139658
Phases
Conditions
Venous Thromboembolism
Interventions
Lead sponsor
Boehringer Ingelheim
Results first posted
2014-01-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01139658-69cceebc